Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Assets for 16 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly Assets changed N/A to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $1.4 billion for FY2025, N/A changed from the prior year.
  • Assets for Q4 2025 was $1.4 billion at Cytokinetics, down from $1.4 billion in the prior quarter.
  • The five-year high for Assets was $1.5 billion in Q2 2024, with the low at $564.3 million in Q2 2021.
  • Average Assets over 5 years is $993.8 million, with a median of $856.3 million recorded in 2022.
  • The sharpest move saw Assets skyrocketed 124.9% in 2021, then tumbled 31.17% in 2023.
  • Over 5 years, Assets stood at $841.3 million in 2021, then grew by 20.62% to $1.0 billion in 2022, then fell by 18.77% to $824.3 million in 2023, then soared by 74.21% to $1.4 billion in 2024, then fell by 0.8% to $1.4 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $1.4 billion, $1.4 billion, and $1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.